Strand Therapeutics is a pioneering biotech startup that is developing a unique platform for creating programmable, long-acting mRNA therapeutics. These therapeutics are designed to deliver precise, multi-functional treatments that could potentially cure various diseases. The company's groundbreaking technology allows mRNA to target only diseased cells, thereby increasing the therapeutic window and reducing potential harm to healthy cells. This is achieved by programming logic-based circuits into the mRNA, enabling it to sense different cell types and activate only in the presence of disease.

Strand Therapeutics operates in the biotech market, serving clients in the medical and healthcare sectors. Its primary focus is on developing improved treatment options for cancer and other life-threatening diseases. The company's business model revolves around the development and commercialization of its proprietary mRNA therapeutics. Revenue is generated through the sale of these therapeutics to healthcare providers and institutions.

The company is also open to collaborations and partnerships to expand its programs. As an emerging biotech company, Strand Therapeutics offers vast learning and growth opportunities, including exposure to all aspects of building a company.

Keywords: Biotech, mRNA Therapeutics, Programmable Medicine, Disease Treatment, Cancer Treatment, Healthcare, Autonomous Medicines, Genetic Circuits, Bioengineering, Life-threatening Diseases.